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Abstract 
Background: Genetic selection of Atlantic salmon families better adapted to alternative feed 
formulations containing high levels of vegetable ingredients has been suggested to ensure 
sustainable growth of aquaculture. The present study aimed to identify molecular pathways 
that could underlie phenotypic differences in flesh n-3 long-chain polyunsaturated fatty acid 
(LC-PUFA) levels when fish are fed vegetable oil diets. Liver transcriptome was analyzed 
and compared in four families presenting higher or lower n-3 LC-PUFA contents at two 
contrasting flesh total lipid levels. 
Results: The main effect of n-3 LC-PUFA contents was in the expression of immune 
response genes (38% of all significantly affected genes), broadly implicated in the 
modulation of inflammatory processes and innate immune response. Although genetic 
evaluations of traits used in the breeding program revealed that the chosen families were not 
balanced for viral disease resistance, this did not fully explain the preponderance of immune 
response genes in the transcriptomic analysis. Employing stringent statistical analysis no lipid 
metabolism genes were detected as being significantly altered in liver when comparing 
families with high and low n-3 LC-PUFA flesh contents. However, relaxing the statistical 
analysis enabled identification of potentially relevant effects, further studied by RT-qPCR, in 
cholesterol biosynthesis, lipoprotein metabolism and lipid transport, as well as eicosanoid 
metabolism particularly affecting the lipoxygenase pathway.Total lipid level in flesh also 
showed an important effect on immune response and 8% of significantly affected genes 
related to lipid metabolism, including a fatty acyl elongase (elovl2), an acyl carrier protein 
and stearoyl-CoA desaturase. 
Conclusions: Inter-family differences in n-3 LC-PUFA content could not be related to effects 
on lipid metabolism, including transcriptional modulation of the LC-PUFA biosynthesis 
pathway. An association was found between flesh adiposity and n-3 LC-PUFA in regulation 
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of cholesterol biosynthesis, which was most likely explained by variation in tissue n-3 LC-
PUFA levels regulating transcription of cholesterol metabolism genes through srebp2. A 
preponderance of immune response genes significantly affected by n-3 LC-PUFA contents 
could be potentially associated with disease resistance, possibly involving anti-inflammatory 
actions of tissue n-3 LC-PUFA through eicosanoid metabolism. This association may have 
been fortuitous, but it is important to clarify if this trait is included in future salmon breeding 
programmes. 
Background 
Aquaculture is the fastest growing animal production activity worldwide, supplying an 
increasing proportion of fish for human consumption, estimated at around 50% of total 
supply in 2008 [1]. However, the growth of marine aquaculture is threatened by its excessive 
reliance on fishmeal (FM) and fish oil (FO) from wild stocks for the production of fish feeds, 
which is also an ecologically unsound practice. Almost 89% of the total global production of 
FO is currently used by aquaculture [2] and the future of this activity strongly depends on the 
reduction of dependency on FM and FO and its replacement with alternative ingredients, such 
as vegetable oils (VO) and plant meals, while maintaining fish welfare and health benefits for 
the human consumer. Fish are highly nutritious components of the human diet and the main 
source of essential n-3 long-chain polyunsaturated fatty acids (LC-PUFA). The beneficial 
effects of fatty acids, such as eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA), 
are numerous and important, including protection against a range of cardiovascular and 
inflammatory diseases, as well as neurological disorders [3]. Atlantic salmon (Salmo salar) 
can grow well on diets where FO has been completely replaced by VO but this results in 
lower levels of n-3 LC-PUFA in their flesh, compromising their nutritional value and health-
promoting effects to the human consumer [4]. 
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The use of selective breeding programs to enhance traits of commercial importance is 
becoming increasingly common in aquaculture [5]. It has been suggested that combining 
genetic selection for fish that are more efficient in retaining and/or biosynthesising n-3 LC-
PUFA with changes in commercial diet formulations (i.e., higher levels of inclusion of VO) 
might be a viable strategy to meet growing worldwide demands for aquaculture products, 
without loss of nutritional value. Previous studies have shown wide individual variability in 
the capacity of Atlantic salmon to retain or synthesize n-3 LC-PUFA when fed VO diets [6]. 
Following this, Leaver et al. [7] demonstrated that deposition and/or retention in flesh of 
dietary n-3 LC-PUFA, EPA and DHA, is a highly heritable trait (h2=0.77) in salmon. These 
results have prompted further interest in large-scale in-depth studies exploring genotype × 
nutrient interactions in salmon, analysing whether the genetic background of the fish could 
affect the physiological response to complete dietary replacement of FO by VO [8,9]. In the 
present study we investigated this further by analyzing the transcriptome from liver, the 
primary site of synthesis and export of lipids to extra-hepatic tissues including flesh, from 
four Atlantic salmon families phenotyped for different levels of flesh n-3 LC-PUFA content 
in response to a VO diet. The objective was to identify gene pathways and molecular 
mechanisms that might underlie differences in flesh n-3 LC-PUFA contents when salmon 
families were fed the same low LC-PUFA diet. Furthermore, because n-3 LC-PUFA level is a 
component of, and associated with total lipid content in a tissue, a factorial design was 
chosen in which families containing higher and lower proportions of flesh n-3 LC-PUFA 
were compared at similar flesh total lipid contents.  
Results 
Family lipid contrasts  
Lipid analysis of fifty Atlantic salmon families showed flesh lipid levels ranging from 2.3 to 
5.7% of wet weight, with relative and absolute n-3 LC-PUFA contents varying from 71 to 
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136 (µg/mg lipid) and 314 to 554 (mg/100g flesh), respectively. As expected, high 
correlations between lipid level and n-3 LC-PUFA content were observed (r = -0.65 or 0.70 
for relative and absolute contents, respectively), indicating that only families with near 
identical lipid levels should be compared to avoid confounding effects associated with the 
lipid level factor (additional file 1). Using these results, four families were identified; two 
with high (H) levels of lipid (5 g/100g flesh), and two with low (L) levels of lipid (3.5 g/100g 
flesh) and, within each level of total lipid, the two families had significantly contrasting 
relative n-3 LC-PUFA contents (similarly termed H and L). Therefore, the four families 
constituted a 2 x 2 factorial design, labelling each family by the total lipid/n-3 LC-PUFA 
contrasts as LL, LH, HL and HH, respectively (Table 1), which allowed comparisons of n-3 
LC-PUFA contents at a constant lipid level and, similarly, comparisons of total lipid at 
constant n-3 LC-PUFA levels.  
Microarray analysis 
A two-way ANOVA analysis employing the Benjamini-Hochberg multiple testing correction 
(at a significance level of 0.05 and fold change cut-off of 1.2) was performed to assess 
significant effects of the factors 'n-3 LC-PUFA' and 'total lipid', which returned lists with 43, 
109 and 66 entities for each factor and their interaction, respectively. These significant lists 
were then analyzed in detail and genes were categorized according to their biological 
function, in some cases inferred from mammalian homolog genes (Tables 2 and 3). Because 
the focus of this work was to identify genes that are specifically affected by the trait n-3 LC-
PUFA content without the interference of total lipid level, the interaction between the two 
factors is not presented. Distribution of genes by categories of biological function (excluding 
12-18% non-annotated probes, those representing the same gene or with a miscellaneous 
function) revealed that there was a preponderance of immune response genes significantly 
affected by both factors: 38% by 'n-3 LC-PUFA' and 29% by 'total lipid'. Gene Ontology 
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(GO) enrichment analysis, which enables the identification of GO terms significantly 
enriched in the input entity list when compared to the whole array dataset, revealed that this 
is a true over-representation in the list of genes significantly affected by the 'total lipid' factor 
(Additional file 2). In contrast, genes involved in the broad category of metabolism only 
corresponded to 21% of genes significantly affected by n-3 LC-PUFA content and 30% by 
the 'total lipid' factor. Surprisingly, no lipid metabolism genes were significantly altered in 
liver when comparing families with higher and lower contents of n-3 LC-PUFA in their flesh, 
while about 8% were significantly affected by flesh lipid level. Within these, noteworthy was 
the down-regulation of fatty acyl elongase (elovl2) and of acyl carrier protein transcripts in 
salmon having a higher lipid level in their flesh, independent of LC-PUFA content. On the 
other hand, stearoyl-CoA desaturase was significantly up-regulated in fish with higher lipid 
levels in their flesh. The interaction between both factors is not presented but it did not 
substantially affect lipid metabolism genes. Finally, and in general, genes involved in 
regulation of transcription and signalling were also prevalent, 17% in response to 'n-3 LC-
PUFA' and 12-13% to 'total lipid'.  
Therefore, the results did not identify lipid metabolism pathways that might underlie 
differences in flesh n-3 LC-PUFA composition between families. However, previous studies 
demonstrated that hepatic metabolism genes typically show only low fold changes, even 
when comparing highly contrasting nutritional compositions (e.g., inclusion of 100% FO 
versus 100% VO in diets [8,9]), compared to immune response genes that tend to be 
regulated with higher magnitudes of change [10]. Hence, nutritional data such as the present 
data have been analysed previously without multiple testing correction and this was found to 
result in relevant biological interpretations, when validated by reverse transcription real time 
quantitative PCR (RT-qPCR) [9, 11]. For this reason, we examined the significant effects of 
'n-3 LC-PUFA' without the correction, and from within the list containing 1951 features 
7 
 
(significance level, 0.05; fold change cut-off, 1.2), we identified and categorized all 48 lipid 
metabolism transcripts present (Table 4). An effect on cholesterol metabolism was apparent 
for the factor 'n-3 LC-PUFA, with several genes of the biosynthesis pathway and its 
regulation being down-regulated in fish with a high n-3 LC-PUFA phenotype. In addition, 
glycerophospholipid synthesis, lipid hydrolysis and eicosanoid synthesis and metabolism 
were also affected, while other genes were associated with lipid and fatty acid transport, fatty 
acid synthesis and regulation of lipid metabolism.  
Validation of results by RT-qPCR 
To validate the microarray analysis results, expression of selected genes was quantified by 
RT-qPCR. These genes were chosen from lipid metabolism pathways that were more highly 
affected by the factor 'n-3 LC-PUFA', and also included immune response genes, which was 
the category most highly affected by both 'n-3 LC-PUFA' and 'total lipid' factors. In addition, 
the expression of two fatty acyl desaturases (Δ5fad and Δ6fad) and one elongase (elovl2), 
which are typically responsive to dietary levels of n-3 LC-PUFA were also determined. The 
LC-PUFA biosynthesis pathway was not identified by the microarray analysis as being 
differentially expressed in families with different n-3 LC-PUFA flesh contents but, given the 
potential importance of this pathway in determining n-3 PUFA phenotypes, we specifically 
aimed to verify this result. The RT-qPCR results confirmed that genes involved in LC-PUFA 
biosynthesis were not differentially expressed in families with higher and lower levels of n-3 
LC-PUFA (Table 5). Furthermore, the RT-qPCR results confirmed significant down-
regulation of genes involved in hepatic cholesterol biosynthesis, such as isopentenyl-
diphosphate isomerase (ipi), 7-dehydrocholesterol reductase (7dchr) and sterol regulatory 
element-binding protein 2 (srebp2) in families containing higher levels of n-3 LC-PUFA in 
their flesh although this was only observed when this phenotype was also associated with low 
lipid level, except for 7dchr, which was significantly down-regulated irrespective of lipid 
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level. With regards to lipoprotein metabolism (lipid transport) genes, general trends such as 
the magnitude and direction of change were broadly similar between the microarray and the 
RT-qPCR analysis for the high versus low n-3 LC-PUFA comparison at low lipid contents, 
although RT-qPCR results were not significant. In the case of high lipid contents, the match 
between microarray and RT-qPCR data was less consistent, except for lipoprotein lipase (lpl), 
which was similarly up-regulated albeit non-significantly. Up-regulation of the 
glycerophospholipid biosynthesis pathway in fish with higher n-3 LC-PUFA contents was 
also indicated when associated with high lipid levels, significant for monoacylglycerol O-
acyltransferase 1 (mgat). With regards to the eicosanoid biosynthesis pathway, the microarray 
results could only be confirmed for arachidonic 5-lipoxygenase (alox5). Validation of lipid 
metabolism genes affected by the ' total lipid' factor (Table 6) confirmed the lower expression 
of elovl2 in salmon presenting higher lipid levels in their flesh, independent of LC-PUFA 
content. Finally, good agreement was found between the microarray and RT-qPCR results for 
immune response genes in response to both 'n-3 LC-PUFA' (Table 5) and 'total lipid' (Table 
6) factors.  
Genetic evaluations  
Subsequent to the dietary trial and microarray analyses, genetic evaluations (estimated 
breeding values, EBVs) became available for a range of traits upon which the families are 
under active selection in the breeding program. Given the unexpectedly high preponderance 
of immune response genes identified by transcriptomic analysis, we investigated associations 
with traits that could potentially explain the gene expression data. In this respect, one of the 
most relevant traits was ‘survival to infectious pancreatic necrosis (IPN) virus’, known to be 
almost entirely controlled by a major QTL [12]. Genetic evaluations included data collected 
from a freshwater experimental IPN challenge on full-sibs from the same families as the trial 
fish. Examining the families, selected on their lipid phenotypes, used for transcriptomic 
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analysis it was seen that family HH, containing both high total lipid and high n-3 LC-PUFA 
flesh contents, also showed a high EBV for survival to IPN (selection differential on a 
standardized normal distribution = 1.86 standard deviations), contrasting with -0.83 (LL) -
0.99 (LH) and -1.28 (HL) for the other families, that could introduce a potential for bias in 
interpretation of the transcriptomic responses. However, no such imbalance was present in 
the lower lipid grouping, comparing families LL and LH (additional file 3). 
Discussion 
The present study which ascertained lipid profiles of 50 Atlantic salmon families confirmed 
previous results showing important inter-family variation in the ability to retain n-3 LC-
PUFA in the flesh when fish are fed diets with low levels of these fatty acids [7]. 
Furthermore, even though a high correlation was found between flesh lipid levels and n-3 
LC-PUFA contents, families with the same total lipid level varied significantly in n-3 LC-
PUFA contents. In the present study we did not examine whether these differences have a 
genetic basis, as this was established previously [7], but instead aimed to identify molecular 
pathways whose transcriptional regulation might underlie the phenotypic differences, 
independent of lipid content.  
LC-PUFA biosynthesis 
Differences in flesh n-3 LC-PUFA content in individuals fed the same diet is likely to arise 
from either selective incorporation and retention of fatty acids supplied by the diet or from 
biosynthesis from precursors in tissues such as the liver. In the present study we performed a 
transcriptomic study to identify molecular mechanisms potentially underlying flesh n-3 LC-
PUFA phenotypes. Expression of candidate genes of the LC-PUFA biosynthesis pathway 
were also quantified as there was good evidence that these genes are transcriptionally 
regulated and that mRNA levels correlate with enzymatic activity of this pathway [13,14], 
and so this appeared a likely mechanism that required specific investigation. Flesh was the 
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target tissue for analysis of the n-3 LC-PUFA retention trait because salmon accumulate lipid 
reserves in muscle and this is the main product for human consumption, and so its 
composition will affect the health-promoting properties of salmon. However, hepatic tissue 
was analyzed for effects on gene expression since the production of both LC-PUFA and the 
lipoproteins that transport them to the tissues takes place mainly in the liver [15].  
The transcriptomic analysis revealed few effects of the n-3 LC-PUFA factor on 
metabolism in general and, in particular, a lack of effect on lipid metabolism genes, when the 
statistical analysis employed multiple testing correction. However, this correction is typically 
not used when examining effects of diet and genetic background on metabolic genes, which 
tend to show subtle, but physiologically relevant, changes (9,11,16). Without multiple testing 
correction we were able to identify pathways of lipid metabolism that might be altered in 
response to this factor, although a clear mechanism for the observed inter-family differences 
in n-3 LC-PUFA content was not identified. Potential effects on lipid transport and 
lipoprotein metabolism were indicated by the presence of two apolipoprotein A4 transcripts 
(apoa4a and b), a low density lipoprotein (LDL) receptor-related protein (lrp1) and a 
lipoprotein lipase (lpl) transcript in the microarray analysis, albeit these were not validated by 
RT-qPCR. In contrast, the RT-qPCR results clearly confirmed that the flesh n-3 LC-PUFA 
phenotype cannot be explained by transcriptional modulation of genes of LC-PUFA 
biosynthesis and so other mechanisms must be in operation. One hypothesis might be that 
phenotypic differences between families originates from the presence of different alleles of 
fatty acyl desaturases and/or elongases encoding proteins with altered biological activity or 
specificity, as described for the nematode Caenorhabditis elegans [17]. 
Effects of n-3 LC-PUFA flesh contents on hepatic cholesterol biosynthesis 
Within the lipid metabolism genes that were differentially expressed in the liver between fish 
showing higher or lower n-3 LC-PUFA contents in flesh, the category of cholesterol 
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biosynthesis and its regulation was the most apparent, based on the number of probes for 
interrelated genes present in this list, all with coordinated regulation indicating reduced 
cholesterol biosynthesis in salmon having higher flesh n-3 LC-PUFA. In addition, and 
inferred by the magnitude of change (i.e., fold-changes), effects were more pronounced in 
fish containing lower flesh lipid levels. These results were confirmed by quantifying the 
expression of three enzymes catalyzing steps in cholesterol biosynthesis (mev, ipi and 7dchr) 
as well as srebp2, a transcription factor that regulates cholesterol synthesis [18]. Furthermore, 
the RT-qPCR analysis indicated that this regulation was only associated with lower flesh 
lipid levels given that in the high lipid group only 7dchr was down-regulated. Therefore, this 
experiment confirmed previous studies suggesting an association between flesh adiposity and 
n-3 LC-PUFA in the regulation of cholesterol biosynthesis in Atlantic salmon families, with 
lean fish showing a higher responsiveness to n-3 LC-PUFA [8]. However, an important novel 
outcome of the present study was the demonstration that the previous results were not solely 
a consequence of a higher dietary intake of cholesterol supplied by a FO diet in contrast to a 
VO diet [11] but also resulted from higher incorporation and increased tissue levels of n-3 
LC-PUFA. The likely explanation for these results is the role of n-3 LC-PUFA as regulators 
of gene transcription, including some implicated in cholesterol biosynthesis, mediated by 
srebp2 [18-20]. Nonetheless, the mechanism for why this response was only observed when 
associated with low flesh lipid levels requires clarification. Recent studies showed that lean 
humans are also more responsive, in terms of plasma lipid and lipoprotein composition, to 
cholesterol-reducing diets containing lower levels of saturated fatty acid and cholesterol than 
obese individuals, and several mechanisms have been proposed to explain this [21]. In the 
present case, the absolute, rather than the relative, level of n-3 LC-PUFA may be the 
determinant factor affecting gene transcription and, in the high lipid group, absolute levels of 
these fatty acids might have been sufficiently high to repress cholesterol biosynthesis genes, 
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even at lower relative n-3 LC-PUFA contents (i.e., group HL). This hypothesis is supported 
by the RT-qPCR analysis comparing the families with regards to lipid level, HL/LL and 
HH/LH. In the HL/LL comparison, contrasting absolute n-3 LC-PUFA levels of 427 versus 
363 mg/100g flesh, there was down-regulation of both ipi and srebp2 (-3.95 and -2.09, 
respectively), whereas comparison of the families HH/LH, containing 554 versus 468 
mg/100g flesh, showed no difference in the expression of the genes. Similarly, genes 
involved in lipoprotein metabolism, which are also regulated by LC-PUFA through different 
mechanisms [20], also showed more significant changes when comparing fatter and leaner 
salmon with lower LC-PUFA levels, indicating that a similar regulatory mechanism might 
occur. Therefore, the present study is consistent with previous work identifying cholesterol 
and lipoprotein metabolism as pathways significantly and differentially affected by n-3 LC-
PUFA depending on flesh adiposity [8].  
Effects of total lipid level on lipid metabolism  
Lipid level significantly affected expression of lipid metabolism genes, although effects were 
still relatively small (8% of all genes assigned to a biological function category). A 
noteworthy result was the down-regulation of elovl2 (confirmed by RT-qPCR) in salmon 
presenting higher flesh lipid, independent of LC-PUFA content. Elovl2 has substrate 
specificity towards LC-PUFA and is highly responsive to dietary n-3 LC-PUFA levels in 
salmon [22]. However, the expression of this gene is often co-ordinately regulated with other 
genes of LC-PUFA biosynthesis, such as Δ5fad and Δ6fad [9], which was not the case here. 
Hence, the biological significance of this result is not clear and may indicate other roles of 
elovl2 in lipid metabolism. For instance, an association between overexpression of elovl2 and 
enhanced triacylglycerol synthesis and lipid droplet accumulation, as well as induction of 
PPARγ target genes, was shown in mouse preadipocyte cell lines [23]. In addition, elovl2 
was up-regulated in the liver transcriptome of rats with nephrotic syndrome, a condition 
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characterized by hyperlipidemia [24]. Elovl2 was only recently characterized in salmon [22], 
and this is the first indication of an association between its expression and lipid accumulation 
in a non-mammalian vertebrate, with results suggesting that increased lipid level in salmon 
flesh repressed elovl2 expression independent of n-3 LC-PUFA level although this requires 
further investigation. Another gene down-regulated at higher lipid levels was a mitochondrial 
acyl carrier protein, involved in acyl transfer steps, including roles in fatty acid synthesis and 
functioning of the electron transport chain [25], which could conceptually be responding to 
similar regulatory mechanisms affecting elovl2. In contrast, stearoyl-CoA desaturase, 
responsible for the synthesis of monounsaturated fatty acids from saturated precursors, was 
up-regulated in salmon with higher flesh lipid levels. This gene was positively correlated with 
fat accumulation in bovine skeletal muscle [26], consistent with up-regulation in salmon 
families with increased fat stores. 
Possible association between flesh n-3 LC-PUFA contents and immune response   
The predominance of immune response genes responding to total lipid level and, particularly, 
n-3 LC-PUFA contents in salmon flesh was unexpected. This was a true over-representation 
as GO enrichment analysis enabled identification of several GO terms related to regulation of 
immune and inflammatory responses in relation to the total lipid factor. However, as 
mentioned above, the transcriptomic comparison, although balanced for total lipid, was not 
balanced for viral disease resistance (specifically IPN in this case) and, as a consequence, 
higher contrast between families was imposed on the high lipid group (families HL and HH) 
due to the fortuitous selection of family HH presenting a much higher viral resistance EBV. 
Nonetheless, if family HH biased the results of the two-way ANOVA we would expect a 
preponderance of immune-related genes to occur only when comparing these two families, 
presenting higher and lower flesh n-3 LC-PUFA contents at the higher lipid level. In order to 
assess this, t-tests were performed comparing separately the higher versus lower n-3 LC-
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PUFA families at each total lipid level, i.e., LH/LL and HH/HL. A Venn diagram contrasting 
the two t-test significant lists was then performed and when analyzing the genes that were 
similarly affected by n-3 LC-PUFA contents at both higher and lower total lipid level, a 
similar preponderance (33%) of immune response genes was observed (Additional file 4). 
Finally, examination of the fold changes of immune-related genes, indicating magnitude of 
effects, between families with higher and lower contents of n-3 LC-PUFA at either higher or 
lower total lipid levels (Tables 2 and 5), showed no clear evidence of the effect being more 
marked for the high lipid comparison, which is what would be expected if results were caused 
simply by inclusion of family HH in the transcriptomic analysis.  
Hence, there is evidence to suggest that there may be some correlation between flesh n-3 
LC-PUFA contents and immune response in the families analysed. An anti-inflammatory role 
of n-3 LC-PUFA is well established in mammals and fish [27-29]. Immune cells are typically 
rich in arachidonic acid (ARA), the precursor for eicosanoids with a pro-inflammatory action, 
whereas EPA and DHA give rise to eicosanoids that are less biologically active, as well as to 
resolvins and protectins presenting anti-inflammatory properties [30]. Higher incorporation of 
n-3 LC-PUFA in biological membranes of immune cells can modulate immune responses in 
several ways [reviewed in 15,30-33]. They alter the production of inflammatory eicosanoid 
mediators of which they are precursors, directly affect the organization and properties of the 
immune cell membranes with effects on signalling pathways, phagocytic capacity and antigen 
presenting capability, and activate transcription of various genes involved in inflammatory 
responses. Therefore, families with higher tissue levels of n-3 LC-PUFA may show 
differential expression of immune response and inflammation-related genes, as well as of 
genes involved in signalling and regulation of transcription (as observed in the present study). 
Furthermore, although liver is chiefly a metabolic organ, it has other physiological functions 
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including removal of pathogens and antigens from the blood and modulation of immune 
responses, as well as the production of inflammatory mediators [34,35]. 
Related to the above, microarray analysis revealed the presence of several genes that 
intervene in eicosanoid synthesis and metabolism including phospholipase A2 (pla2), 
arachidonate 5-lipoxygenase (alox5), thromboxane-A synthase (thas), prostaglandin I2 
synthase (ptgis) and 15-hydroxyprostaglandin dehydrogenase [36]. However, RT-qPCR only 
confirmed up-regulation of hepatic alox5 in families presenting higher flesh n-3 LC-PUFA 
and, given that alox5 acts on LC-PUFA of both n-3 and n-6 series and that ARA levels 
generally accompanied the n-3 LC-PUFA phenotype (Table 1), it cannot be ascertained 
whether this transcript was responding to higher levels of membrane ARA or EPA and hence 
if it would result in increased pro-inflammatory 4-series, or less potent 5-series, leukotrienes 
[37].  
The immune response genes whose expression was correlated with 'n-3 LC-PUFA' are 
mainly involved in the modulation of inflammatory processes and innate immune response to 
pathogens, which are particularly important in fish species and that can be easily 
compromised in aquaculture conditions [38]. We could speculate that the changes in 
expression may give enhanced protection from inflammation or pathological conditions in 
fish with higher n-3 LC-PUFA in their tissues. Up-regulation associated with high flesh n-3 
LC-PUFA was noted in expression of NACHT domain containing protein, tripartite motif-
containing protein 25 (trim25), c-c motif chemokine 13 precursor (ccl13), leukocyte cell-
derived chemotaxin 2 precursor (lect2), tissue factor pathway inhibitor a, pentraxin and 
cathepsin K. In contrast, down-regulation in the high n-3 LC-PUFA families was observed 
for MHC class I (mostly in the high total lipid group), myelin and lymphocyte protein (mal). 
NACHT domain containing proteins are pathogen-sensing molecules (recognizing 
intracellular pathogen-associated molecular patterns – PAMPs) implicated in early host 
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defence, inflammation and innate immune signalling pathways in mammals [39], by 
activating transcription of MHC class II and the apoptotic pathway. The trim25 protein is 
involved in antiviral innate immune responses through activation of signalling pathways 
leading to production of interferons and in teleost cells TRIM genes are induced in response 
to viral infections [40,41]. The ccl13 (also known as monocyte chemotactic protein 4) and 
lect2 proteins are both involved in inflammation, having roles in attracting monocytes and T 
lymphocytes in tissues exposed to exogenous pathogens, and neutrophil chemotactic function 
[42,43]. Expression of lect2 was increased in fish liver and spleen after bacterial infections 
[43]. Tissue factor pathway inhibitor inhibits the initial reactions of the blood coagulation 
cascade and modulates cell proliferation, and may protect vascular tissue in inflammatory 
conditions in mammals [44]. Cathepsin K mediates immune responses in cells, having a 
critical role in signalling events proximal to the Toll-like receptor 9 (TLR9) that has a 
fundamental role in pathogen recognition (recognizing PAMPs) and activation of mammalian 
innate immunity [45]. Finally, pentraxins are pattern recognition proteins of the innate 
immune system that play a role in the acute phase response, activating complement pathways 
to clear pathogens in both mammals and fish [46,47]. In this case, up-regulation of pentraxin 
in salmon with higher n-3 LC-PUFA in their flesh was only observed with high lipid levels. 
Similarly, down-regulation of the MHC class I transcript was observed only in the high lipid 
group. In mammalian studies, high LC-PUFA contents (EPA, DHA and ARA) reduced cell 
surface expression of MHC I, decreasing antigen presentation and altering T-cell signalling 
[34,35]. Therefore, the high IPN resistance genotype observed in family HH in later genetic 
evaluations of the families could potentially involve effects on both the complement pathway 
and T-cell mediated immunity, and involve co- or post-translational modification of proteins 
by N-linked glycosylation through up-regulation of dolichyl-diphosphooligosaccharide-
protein glycosyltransferase subunit 4 (Table 2; [48]). Given the high economic impact of IPN 
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in salmonid culture, identification of genes potentially involved in the progression of the 
disease using transcriptomic approaches is already in progress [49]. Finally, down-regulation 
of mal, associated with T-cell differentiation and signal transduction [50], was observed at 
higher n-3 LC-PUFA levels.  
As mentioned above, several immune response-related genes were also affected by the 
total lipid factor with results validated by RT-qPCR. However, we cannot exclude the 
possibility that this results from the strong correlation between total lipid levels and absolute 
LC-PUFA contents, which makes it difficult to dissociate both factors.  
Conclusions 
It has been demonstrated earlier that LC-PUFA flesh content is a highly heritable trait [7], but 
the present study has shown that the underlying mechanisms do not appear to involve 
changes in the expression of lipid metabolism genes, including the LC-PUFA biosynthesis 
pathway. Other possible mechanisms, such as alleles with different biological activity, 
require investigation. The present study revealed an association between flesh adiposity and 
n-3 LC-PUFA in the regulation of cholesterol biosynthesis, which was down-regulated by 
higher n-3 LC-PUFA levels but only in the lean families. This response was not caused by 
dietary factors, given that the fish were all fed the same VO-based diet, and is most likely 
explained by variation in tissue n-3 LC-PUFA levels, regulating transcription of cholesterol 
metabolism genes through srebp2. Furthermore, the transcriptional repression of these genes 
may be sensitive to the absolute levels of these fatty acids in the tissues, which could explain 
the lack of regulation when comparing the families containing higher flesh lipid levels. It is 
likely that n-3 LC-PUFA exert similar roles in regulation of gene expression in fish as in 
mammals and, furthermore, fish might be a useful model to study important relationships 
between genetics, diet, adiposity/obesity and lipoprotein/cholesterol metabolism. However, 
unexpected differences were found in the expression of genes implicated in the modulation of 
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inflammatory processes and innate immune response between families differing in lipid 
composition, both in terms of total lipid level and, particularly, n-3 LC-PUFA contents. 
Although the evidence is generally circumstantial it is important to clarify this association if 
flesh n-3 LC-PUFA level is included as a trait for genetic selection in Atlantic salmon 
breeding programmes. If such a relationship is confirmed, the data suggest that the 
underlying mechanism might involve anti-inflammatory actions of tissue n-3 LC-PUFA on 
the eicosanoid biosynthesis pathway (particularly affecting the lipoxygenase pathway), 
although direct effects through regulation of transcription of immune genes or more indirectly 
through changes in architecture and properties of immune cell membranes are also possible.  
Methods  
Feeding trial and sampling  
Fifty full-sib families selected from the 200 broodstock families of the Landcatch Natural 
Selection (LNS) Atlantic salmon breeding program (2005-strip year-group) were specifically 
selected for the feeding trial.  On the basis of parental genetic evaluations, 25 high flesh lipid 
contrasting with 25 low flesh lipid families were identified, and 35 fish (initial weight, ~100 
g) from each family were transferred and grown in communal seawater pens (Marine 
Harvest, Ardnish, Scotland). All fish were tagged with electronic transponders (PIT tags) to 
allow family identification while rearing in a common environment. After acclimation, the 
fish were grown for 12 weeks on the same low FM/high VO diet (Nutreco ARC, Stavanger, 
Norway) containing 25 % FM and 44 % plant meals and a VO blend including rapeseed 
oil/palm oil/camelina oil (2.5:1.5:1). At the end of the trial (378 g average weight), flesh 
samples (Norwegian Quality Cut) were collected, frozen on dry ice and stored at -20 ºC until 
lipid analysis. Liver samples were also taken and stored at -70 ºC for subsequent molecular 
analyses.  
Lipid analysis and choice of families for transcriptomic comparisons 
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The 50 selected families were screened for their ability to retain and/or synthesize n-3 LC-
PUFA when fed a low FM/high VO diet. De-boned and skinned flesh samples were 
combined into 3 pools per family for lipid analysis. Total lipids were extracted and 
determined gravimetrically from 1-2 g of pooled flesh [51]. Fatty acid methyl esters (FAME) 
were prepared by acid-catalyzed transesterification of total lipids [52]. Following 
purification, FAME were separated and quantified by gas-liquid chromatography as 
described in [9]. These data were used to select four families for transcriptomic analysis: two 
with equivalent high levels of lipid ‘H’, and two with equivalent low levels of lipid ‘L’. 
Within each level of total lipid, two families with significantly contrasting (p<0.05 on 
Student’s t-test; Graphpad Prism™, version 4.0, Graphpad Software, San Diego, CA) relative 
n-3 LC-PUFA levels (similarly termed H and L) were identified (Table 1).   
RNA extraction and purification 
Hepatic tissue (200 mg) from ten individuals per family was rapidly homogenized in 2 ml 
TRI Reagent (Ambion, Applied Biosystems, Warrington, U.K.). Total RNA was isolated, 
following manufacturer’s instructions, and RNA quality and quantity was assessed by gel 
electrophoresis and spectrophotometry (NanoDrop ND-1000, Thermo Scientific, 
Wilmington, U.S.A.), respectively. Equal amounts (50 µg) of total RNA were pooled from 
two individuals to produce five biological replicates per family, which were further purified 
by mini spin-column purification (RNeasy Mini Kit, Qiagen, Crawly, U.K.). 
Microarray hybridization and analysis 
A custom-made Atlantic salmon oligoarray with 44K features per array on a four-array-per-
slide format (Agilent Technologies, Cheshire, U.K.), with experimental features printed 
singly was used; described more fully in [53]. The probes were co-designed at the Institute of 
Aquaculture, University of Stirling, U.K. and Nofima, Norway, with array design available in 
the EBI ArrayExpress database (http://www.ebi.ac.uk/arrayexpress/arrays/browse.html) 
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under accession number A-MEXP-2065. The features were mainly derived from a core set of 
Atlantic salmon Unigenes (NCBI) supplemented with other unique cDNAs derived from 
Genbank and the Atlantic Salmon Gene Index 
(http://compbio.dfci.harvard.edu/tgi/tgipage.html). Probe annotations were derived from 
Blastx comparisons across four protein databases, detailed elsewhere [54]. The entire 
experiment comprised 20 hybridizations (5 slides): 4 groups (families) × 5 biological 
replicates (pools of 2 individuals each). 
Indirect labelling was employed in preparing the microarray targets, as described in detail 
previously [8]. Antisense amplified RNA (aRNA) was produced from 500 ng of each total 
RNA purification reaction using the Amino Allyl MessageAmpTM II aRNA Amplification 
Kit (Ambion, Applied Biosystems), following the manufacturer’s methodology followed by 
Cy3 or Cy5 fluor (PA23001 or PA25001, GE HealthCare) incorporation through a dye-
coupling reaction. 
The hybridizations were performed using SureHyb hybridisation chambers (Agilent) in a 
DNA Microarray Hybridisation Oven (Agilent). Sample order was semi-randomized, with 
one replicate per experimental group being loaded into each slide. Each biological replicate 
pool was co-hybridized in a two-dye experiment with a single pooled reference sample. This 
pooled reference comprised equal quantitites of aRNA from all 20 biological replicate pools. 
Microarry manufacturer’s instructions were followed. Briefly, for each hybridization, 825 ng 
of Cy3-labelled experimental biological replicate and Cy5-labelled reference pool were 
combined. A fragmentation master mix containing 10× blocking agent (Agilent), 25× 
fragmentation buffer (Agilent) and nuclease-free water, was dispensed into the Cy-dyes mix. 
After incubating in the dark at 60 ºC for 30 mins, 2× GE Hybridization buffer (pre-heated to 
37 ºC; Agilent) was added, contents gently mixed, spun at 16K g for 1 min and finally kept 
on ice until loaded onto the microarray slides. Hybridization was carried out in the oven 
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rotator (Agilent) at 65 ºC and 10 rpm for 17 h. Post-hybridization washes were carried out in 
EasyDipTM Slide staining containers (Canemco Inc., Quebec, Canada). After disassembling 
the array-gasket sandwiches submersed in wash buffer 1 (Agilent) at room temperature, the 
microarray slides were incubated in wash buffer 1 for 1 min at 31 ºC in a Stuart Orbital 
Incubator S150 rotating at 150 rpm, and then a further 1 min at 31 ºC at 150 rpm in wash 
buffer 2 (Agilent). A final dip in wash buffer 2 at room temperature was performed, after 
which the slides were dried by centrifugation (500 xg for 6 mins) and kept in a desiccator and 
in the dark until scanned, the same day. 
Scanning was performed at 5 µm resolution using an Axon GenePix 4200AL Scanner 
(MDS Analytical Technologies, Wokingham, Berkshire, U.K.). Laser power was kept 
constant (50 %) and the “auto PMT” function within the acquisition software (v.4) was 
enabled to adjust PMT for each channel such that less than 0.1 % of features were saturated 
and that the mean intensity ratio of the Cy3 and Cy5 signals was close to one. Agilent Feature 
Extraction Software (v 9.5) was used to identify features and extract fluorescence intensity 
values from the resultant TIF images. Analysis of the intensity values was performed in the 
GeneSpring GX version 11 analysis platform (Agilent Technologies, Wokingham, Berkshire, 
U.K.). All intensity values <0.1 were set to equal 0.1 followed by a Lowess normalization. 
After removing control features, four quality filtering steps were carried out sequentially 
using a range of quality control metrics produced by the Agilent Feature Extraction software 
to remove features that were saturated, non uniform, population outliers and spots non-
significantly different from background. This gave a final list of 32,566 probes that were 
eligible for statistical analysis. Experimental annotation complied fully with minimum 
information about a microarray experiment (MIAME) guidelines [55]. The experimental 
hybridizations and further methodological details are archived on the EBI ArrayExpress 
database under accession number E-TABM-1204. 
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Normalized and quality-filtered fluorescence intensity data was analysed in GeneSpring 
GX v11 by two-way ANOVA, which examined the explanatory power of the variables ‘total 
lipid’ and ‘n-3 LC-PUFA’ and the interaction between the two, at a significance level of 0.05 
and intensity ratio (i.e., fold change) cut-off of 1.2. Two sets of analysis were performed, 
with or without Benjamini-Hochberg multiple testing correction. In the set with multiple 
testing correction, GO enrichment analysis was performed at a significance level of 0.05. 
RT-qPCR 
Expression of selected genes found by microarray analysis to be significantly affected by 
either ‘total lipid’ or ‘n-3 LC-PUFA’ content was quantified by RT-qPCR. In addition, the 
expression of two fatty acyl desaturases (Δ5fad and Δ6fad) and one elongase (elovl2) that are 
typically responsive to dietary n-3 LC-PUFA was determined. Primers were designed using 
Primer3 software (http://biotools.umassmed.edu/bioapps/primer3_www.cgi) (Table 7). Two 
reference genes, elongation factor-1α (elf-1α) and β-actin, were also quantified.  
For RT-qPCR, 2 µg of column-purified total RNA per sample was reverse transcribed into 
cDNA using the High-Capacity cDNA RT kit (Applied Biosystems, Paisley, U.K.), following 
manufacturer’s instructions, but using a mixture of the random primers (1.5 µl as supplied) 
and anchored oligo-dT (0.5 µl at 400 ng/µl, Eurofins MWG Operon, Ebersberg, Germany). 
Negative controls (containing no enzyme) were performed to check for genomic DNA 
contamination. A similar amount of cDNA was pooled from all samples and the remaining 
cDNA was then diluted 20-fold with water. RT-qPCR analysis used relative quantification 
with the amplification efficiency of the primer pairs being assessed by serial dilutions of the 
cDNA pool. Amplifications were carried out in duplicate (Quantica, Techne, Cambridge, 
U.K.) in a final volume of 20 µl containing 5 µl or 2 µl (for more highly expressed genes) 
diluted (1/20) cDNA, 0.5 µM of each primer (0.4 µM for lect2) and 10 µl AbsoluteTM 
QPCR SYBR® Green mix (ABgene). Amplifications were carried out with a systematic 
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negative control (NTC-non template control, containing no cDNA). The RT-qPCR profiles 
contained an initial activation step at 95 °C for 15 min, followed by 30 to 40 cycles: 15 s at 
95 °C, 15 s at the specific primer pair annealing temperature (Ta; Table 7) and 15 s at 72 °C. 
After the amplification phase, a melt curve of 0.5 °C increments from 75 ºC to 90 °C was 
performed, enabling confirmation of the amplification of a single product in each reaction. 
Non-occurrence of primer-dimer formation in the NTC was verified. RT-qPCR product sizes 
and presence of single bands were checked by agarose gel electrophoresis. Additionally, 
sequencing of amplicons corresponding to new primer designs enabled the confirmation of 
identities and presence of single sequences for all genes except for trim25, as the sequencing 
result was of insufficient quality to conclude on the presence of a single gene product, and 
lrp1, for which results were indicative of quantification of a highly similar, recently 
duplicated, gene.  
Results were analyzed by the ΔΔCt method using the relative expression software tool 
(REST 2009, http://www.gene-quantification.info/), which employs a pair wise fixed 
reallocation randomization test (10,000 randomizations) with efficiency correction [56], to 
determine the statistical significance of expression ratios (or gene expression fold-changes) 
between two treatments. 
Genetic evaluations of traits used in the salmon breeding program 
Parental evaluations were confirmed by subsequent analysis of family sibs (at harvest weight, 
some 1 year after the present study) for a range of traits upon which the breeding program 
families are under active selection including flesh lipid composition parameters (total lipid) 
as well as EBVs for weight at harvest, precocious maturation, flesh colour, sealice resistance 
and resistance to a viral infection (IPN).  
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Table 1 Lipid phenotypes of families chosen for molecular analysis. Indicated are levels 
of total lipid (g/100g flesh, wet weight), and relative and absolute contents of total n-3 LC-
PUFA and of the n-6 LC-PUFA arachidonic acid (ARA) in the flesh (n=3 pools) of the 4 
Atlantic salmon families used in the transcriptomic analysis. Asterisks signify significant 
differences between the two families with the same total lipid content. 
Family Total Lipid  n-3 LC-PUFA  ARA 
   Relative Absolute  Relative Absolute 
 (g/100g flesh)  (µg/mg lipid) (mg/100g flesh)  (µg/mg lipid) (mg/100g flesh) 
LL 3.5 ± 0.4  105.1 ± 3.8 * 363.0 ± 30.3  3.45 ± 0.13 * 11.93 ± 1.00 
LH 3.5 ± 0.7  133.8 ± 4.8 * 468.0 ± 92.9  4.25 ± 0.06 * 14.87 ± 2.94 
        
HL 5.1 ± 0.8  83.7 ± 14.0 * 426.9 ± 103.2  2.70 ± 0.53 13.81 ± 3.80 
HH 5.0 ± 0.7  112.0 ± 7.9 * 554.3 ± 50.7  3.67 ± 0.63 18.04 ± 2.09 
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Table 2 Liver transcripts differentially expressed when examining the explanatory 
power of the factor 'n-3 LC-PUFA' content in flesh of four families of Atlantic salmon 
fed the same low FM/high VO diet. Results were obtained by two-way ANOVA analysis 
(p<0.05; fold change cut-off of 1.2) with Benjamini-Hochberg multiple testing correction. 
Transcripts (43 probes; 12% unknowns) are arranged by categories of biological function 
and, within these, by p-value. Indicated are also the probe names and the expression ratio 
determined separately between families with high vs low n-3 LC-PUFA contents, for each 
total lipid level. Percentages of distribution of genes within each category do not include non-
annotated probes, those representing the same gene or with a miscellaneous function.  
Probe name Gene High/Low LC-PUFA p- 
  L Lipid 
(LH/LL) 
H Lipid 
(HH/HL) 
value 
     
Metabolism (21%) 
     
Energy metabolism (4%) 
Ssa#S31995754 Cytochrome c oxidase subunit 2 7.1 - 1.0 0.0001 
  
Protein and amino acid metabolism (13%) 
Ssa#CB502423 N-acetylated alpha-linked acidic dipeptidase-like 1 3.7 79.8 0.0011 
Ssa#STIR03710 Proteasome subunit beta type-9 precursor - 14.9 - 1.1 0.0026 
Ssa#S31993738_S Ubiquitin-conjugating enzyme E2 - 3.3 - 1.4 0.0188 
    
Xenobiotic and oxidant metabolism (4%) 
Ssa#S18892279 Cytochrome P450 1A 1.8 1.4 0.0096 
Ssa#STIR00161_2 Cytochrome P450 1A 1.9 1.4 0.0160 
Ssa#STIR00161_3 Cytochrome P450 1A 2.5 1.8 0.0213 
Con_CANDS_13 Cytochrome P450 1A 2.0 1.4 0.0494 
    
Translation (8%) 
Ssa#STIR26031 Mitochondrial 28S ribosomal protein S34 - 11.1 1.5 0.0017 
Ssa#S18867312 Ribonuclease UK114 1.4 1.4 0.0450 
    
Regulation of transcription (17%) 
Ssa#S35510106 Zinc finger protein 367 - 1.4 6.5 0.0026 
Omy#S18104058 Zinc finger protein 235 4.1 2.3 0.0058 
Ssa#TC111702 Reverse transcriptase-like protein - 1.3 4.6 0.0104 
Ssa#TC112002 Retinoid X receptor beta 1.0 - 19.1 0.0134 
    
Signalling and protein modification (17%) 
Ssa#STIR15776 Dolichyl-diphosphooligosaccharide-protein glycosyltransferase subunit 4 - 1.7 123.3 0.0000 
Ssa#STIR23530 Dolichyl-diphosphooligosaccharide-protein glycosyltransferase subunit 4 - 1.9 115.6 0.0000 
Ssa#STIR03642 Dolichyl-diphosphooligosaccharide-protein glycosyltransferase subunit 4 - 1.7 68.1 0.0000 
Ssa#STIR01857 Dolichyl-diphosphooligosaccharide-protein glycosyltransferase subunit 4 - 1.5 125.5 0.0001 
Ssa#STIR31840 Sphingomyelin phosphodiesterase acid transcript variant 1 2.1 2.3 0.0303 
Ssa#STIR07369 RAF1 proto-oncogene serine/threonine-protein kinase 1.8 1.3 0.0343 
Ssa#S35552908 Tyrosine 3-monooxygenase/tryptophan 5-monooxygenase activation 
protein, epsilon polypeptide 
- 1.6 - 2.1 0.0455 
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Immune response (38%) 
Ssa#S35536179 similar to novel NACHT domain containing protein 2.4 1.8 0.0026 
Ssa#S35516341 Tripartite motif-containing protein 25 (trim25) 5.2 6.7 0.0066 
Ssa#S30241035 MHC class I - 1.3 - 26.0 0.0079 
Ssa#STIR02298 c-c motif chemokine 13 precursor (ccl13) 4.4 3.0 0.0100 
Ssa#S35581943 Myelin and lymphocyte protein (mal) - 22.2 - 25.0 0.0100 
Ssa#KSS3969 Leukocyte cell-derived chemotaxin 2 precursor (lect2) 4.6 7.1 0.0134 
Ssa#STIR15577 Tissue factor pathway inhibitor a 22.3 1.7 0.0135 
Omy#S15332652 Pentraxin - 1.1 199.4 0.0172 
Ssa#TC70262 Cathepsin K 1.4 2.3 0.0279 
Ssa#S35558945 Tripartite motif-containing protein 25 (trim25) 4.8 6.5 0.0347 
  
Miscellaneous/unknown function 
Ssa#STIR09736 Transmembrane protein 42 2.3 1.9 0.0009 
Ssa#S35519407 Tetratricopeptide repeat protein 23  3.7 1.0 0.0011 
Ssa#STIR02307 Family with sequence similarity member a (FAM36A) 1.3 3.6 0.0026 
Omy#BX309274 X-ray repair complementing defective repair in Chinese hamster cells 3 - 1.0 - 8.0 0.0100 
Ssa#STIR21287 Solute carrier family 30 (zinc transporter) member 7 2.1 1.5 0.0100 
Ssa#S35521859_S Family with sequence similarity member a (FAM36A) - 1.1 4.8 0.0358 
Ssa#S18842295 Alveolin 1.7 4.6 0.0422 
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Table 3 Liver transcripts differentially expressed when examining the explanatory 
power of the variable 'total lipid' level in flesh of four families of Atlantic salmon fed the 
same low FM/high VO diet. Results were obtained by two-way ANOVA analysis (p<0.05; 
fold change cut-off of 1.2) with Benjamini-Hochberg multiple testing correction. Transcripts 
(109 probes; 18% unknowns) are arranged by categories of biological function and, within 
these, by p-value. Indicated are also the probe names and the expression ratio determined 
separately between families with high vs low total lipid level, for each n-3 LC-PUFA 
grouping. Percentages of distribution of genes within each category do not include non-
annotated probes, those representing the same gene or with a miscellaneous function. 
Probe name Gene High/Low Lipid p- 
  Lo LC-PUFA 
(HL/LL) 
Hi LC-PUFA 
(HH/LH) 
value 
     
Metabolism (30%) 
 
Lipid metabolism (8%) 
Ssa#STIR02479 Butyrophilin subfamily 2 member A2 precursor 7.76 1.23 0.0001 
Ssa#STIR03356 Acyl carrier protein, mitochondrial precursor - 5.17 - 1.55 0.0004 
Ssa#STIR00151_3 Polyunsaturated fatty acid elongase (elovl2) - 1.40 - 1.87 0.0190 
Ssa#STIR00151_2 Polyunsaturated fatty acid elongase (elovl2) - 1.28 - 1.97 0.0238 
Con_CANDS_03 Polyunsaturated fatty acid elongase (elovl2) - 1.33 - 1.82 0.0310 
Ssa#STIR24266 Acyl carrier protein, mitochondrial precursor - 2.88 - 1.52 0.0312 
Ssa#STIR21802 Stearoyl-CoA desaturase 3.53 3.17 0.0324 
Ssa#STIR00151_4 Polyunsaturated fatty acid elongase (elovl2) - 1.41 - 1.82 0.0393 
Ssa#S35501441_S Acyl carrier protein, mitochondrial precursor - 2.65 - 1.44 0.0457 
Ssa#KSS4634 Stearoyl-CoA desaturase 3.52 2.82 0.0486 
     
Energy metabolism and generation of precursor metabolites (11%) 
Ssa#S31995754 Cytochrome c oxidase subunit 2 6.57 - 1.12 0.0002 
Ssa#STIR03496 LYR motif-containing protein 5 1.20 1.48 0.0233 
Ssa#STIR03740 6-Phosphogluconate dehydrogenase, decarboxylating 1.60 1.93 0.0238 
Ssa#TC106663 Creatine kinase, testis isozyme 1.76 1.46 0.0380 
Ssa#STIR19155 NADH dehydrogenase iron-sulfur protein 7 1.21 2.30 0.0409 
Ssa#STIR12872 V-type ATPase B subunit - 1.19 - 1.24 0.0419 
 
Protein and amino acid metabolism (4%) 
Ssa#STIR03710 Proteasome subunit beta type-9 precursor 1.94 25.52 0.0001 
Ssa#S30294677 Serine protease HTRA1 precursor (Serine protease 11) 3.42 2.44 0.0089 
 
Carbohydrate metabolism (4%) 
Ssa#TC106766 Glycogenin 8.64 1.67 0.0093 
Ssa#S30290426 Serine dehydratase-like 1.60 1.72 0.0393 
     
Xenobiotic and oxidant metabolism (4%) 
Ssa#S35671757 Extracellular superoxide dismutase 2.18 1.09 0.0061 
Ssa#STIR25620 Microsomal glutathione S-transferase 1 2.45 2.72 0.0096 
Omy#S18159333 Microsomal glutathione S-transferase 1 2.47 3.15 0.0233 
     
Transport (2%) 
Ssa#S35599996 ATPase, H+ transporting, lysosomal, V1 subunit H 45.10 15.16 0.0000 
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Translation (4%) 
Ssa#STIR26031 Mitochondrial 28S ribosomal protein S34 1.19 19.22 0.0000 
Ssa#S30241612 39S ribosomal protein L16 1.30 1.51 0.0324 
     
Regulation of transcription (12%) 
Ssa#STIR06878 Cytosolic iron-sulfur protein assembly 1 - 1.16 - 1.56 0.0106 
Ssa#TC112002 Retinoid X receptor beta 1.20 - 16.00 0.0254 
Omy#S15320037 SWI/SNF-related matrix-associated actin-dependent 
regulator of chromatin a4 
- 1.97 - 1.53 0.0324 
Ssa#CN181280 alpha thalassaemia mental retardation X-linked protein - 3.05 - 6.90 0.0419 
Ssa#S35697153 YLP motif containing 1 - 1.49 - 1.32 0.0428 
Ssa#S35486480 Zinc finger protein 492 - 1.08 - 2.29 0.0452 
     
Signalling and protein modification (13%) 
Ssa#STIR15776 Dolichyl-diphosphooligosaccharide-protein 
glycosyltransferase subunit 4 
- 84.27 2.44 0.0000 
Ssa#STIR23530 Dolichyl-diphosphooligosaccharide-protein 
glycosyltransferase subunit 4 
- 83.34 2.60 0.0000 
Ssa#STIR03642 Dolichyl-diphosphooligosaccharide-protein 
glycosyltransferase subunit 4 
- 49.76 2.34 0.0001 
Ssa#STIR01857 Dolichyl-diphosphooligosaccharide-protein 
glycosyltransferase subunit 4 
- 74.19 2.51 0.0011 
Ssa#S35516167 14 kDa phosphohistidine phosphatase 1.57 1.34 0.0019 
Ssa#STIR11086 Lunatic fringe - 5.47 - 2.00 0.0154 
Ssa#S30263209 HtrA serine peptidase 3 3.71 2.33 0.0154 
Ssa#STIR22920 HCLS1-associated protein X-1 1.73 2.33 0.0390 
Ssa#S35701148 Phosphatase and actin regulator 3 - 1.52 - 65.53 0.0404 
Omy#S15290792 Serine/threonine-protein kinase PLK2 1.70 2.03 0.0468 
     
Immune response (29%) 
Ssa#STIR00130_4 Complement factor H precursor (cfh) - 1.43 - 1.67 0.0012 
Ssa#S35536179 novel NACHT domain containing protein - 1.89 - 2.41 0.0013 
Ssa#S30241035 MHC class I - 1.55 - 30.59 0.0024 
Ssa#S35516341 Tripartite motif-containing protein 25 (trim25) - 5.64 - 4.34 0.0125 
Ssa#S18834140 Complement factor H precursor (cfh) - 1.34 - 1.57 0.0131 
Omy#utu04b09 Complement factor H precursor (cfh) - 1.56 - 1.70 0.0134 
Ssa#STIR15577 Tissue factor pathway inhibitor a 21.03 1.59 0.0151 
Ssa#S35558236 C-type lectin domain family 16, member A 4.59 2.25 0.0190 
Ssa#STIR10409 CD83 antigen precursor 1.98 1.68 0.0238 
Omy#S15332652 Putative pentraxin - 1.33 159.84 0.0246 
Ssa#S35685271 GTPase IMAP family member 7 -168.44 - 4.09 0.0263 
Ssa#S35551959 Duodenase-1 - 2.94 - 2.77 0.0349 
Ssa#S35558945 Tripartite motif-containing protein 25 (trim25) - 5.74 - 4.28 0.0373 
Ssa#S35685273 Lactose-binding lectin l-2 precursor putative 1.56 4.04 0.0380 
Ssa#S31977617 Scavenger receptor cysteine-rich type 1 protein m130 - 1.31 - 2.05 0.0404 
Ssa#STIR04893 Lactose-binding lectin l-2 precursor putative 1.57 4.15 0.0419 
Ssa#S30264865 Indoleamine-pyrrole 2,3-dioxygenase 2.83 1.06 0.0444 
Ssa#S31981622 Granzyme A - 5.31 - 4.33 0.0444 
Ssa#S35685718 CD83 antigen precursor 2.03 1.58 0.0462 
Ssa#KSS3969 Leukocyte cell-derived chemotaxin 2 precursor (lect2) 3.16 4.86 0.0486 
     
Structural proteins (10%) 
Ssa#STIR03004 Troponin I, slow skeletal muscle - 202.28 - 135.03 0.0000 
Ssa#CK891024 Vitelline envelope protein gamma 1.07 - 15.43 0.0002 
Ssa#STIR02053 Troponin I, slow skeletal muscle - 70.21 - 10.07 0.0005 
Omy#S34312003 similar to Titin (Connectin) - 44.29 - 29.86 0.0013 
Omy#S15317515 Type I keratin E7 5.08 2.43 0.0167 
Ssa#STIR05140 Troponin I, slow skeletal muscle - 13.16 - 14.20 0.0124 
Ssa#STIR08802 Myosin regulatory light chain 2, smooth muscle isoform 1.55 1.34 0.0324 
     
Miscellaneous/unknown function 
Ssa#S35519407 Tetratricopeptide repeat protein 23  3.64 1.02 0.0012 
Ssa#S35584894 NCK-associated protein 1-like - 1.82 - 1.70 0.0019 
Ssa#S35521859_S FAM36A 1.11 5.75 0.0047 
Ssa#STIR02307 FAM36A 1.16 3.31 0.0058 
Ssa#TC87798 Envelope polyprotein - 1.83 - 1.03 0.0233 
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Ssa#STIR20319 TPA-induced transmembrane protein - 1.09 1.75 0.0233 
Ssa#TC110493_S Beta-3-galactosyltransferase 6.80 1.80 0.0233 
Ssa#S30270166 Transmembrane protein 37 2.13 1.90 0.0254 
Ssa#STIR08658 Tetraspanin-3 putative - 3.20 - 1.47 0.0312 
Ssa#S30293470 Deoxyribonuclease gamma precursor 2.19 2.85 0.0366 
Ssa#S35667723 Dynein, cytoplasmic 1, light intermediate chain 2 - 1.90 - 1.48 0.0366 
Ssa#CX354464 Retinol dehydrogenase 12 2.37 2.35 0.0373 
Ssa#S35582016 Type I iodothyronine deiodinase 1.51 1.74 0.0380 
Ssa#S35515630 C7orf57 1.32 1.13 0.0380 
Ssa#STIR15617 FAM36A 1.02 4.60 0.0403 
Ssa#STIR31448 osteopontin-like - 4.84 - 1.58 0.0419 
Ssa#STIR26263 Anterior gradient protein 2 homolog precursor  3.72 1.68 0.0419 
Ssa#TC65497_S Adipocyte plasma membrane-associated protein 2.50 1.64 0.0419 
Ssa#TC93681 Ring finger protein 44  - 1.23 - 1.17 0.0455 
Ssa#EG819142 Glutaminyl-peptide cyclotransferase-like - 1.11 - 1.49 0.0455 
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Table 4 Lipid metabolism genes differentially expressed in the liver of fish having high 
or low flesh n-3 LC-PUFA contents. Results were obtained by two-way ANOVA analysis 
(p<0.05; fold change cut-off of 1.2) without multiple testing correction (n=1951 total 
features). Transcripts are arranged by functional categories and, within these, by p-value. 
Indicated are also the probe names and the expression ratio between families determined 
separately for each total lipid level.  
Probe name Gene High/Low LC-PUFA p- 
  L Lipid 
(LH/LL) 
H Lipid 
(HH/HL) 
value 
     
Cholesterol biosynthesis, metabolism and regulation 
Omy#S15288895 Sterol-C4-methyl oxidase-like 1.84 1.32 0.0033 
Ssa#STIR00031_3 7-dehydrocholesterol reductase (7dchr) - 1.55 - 1.48 0.0036 
Ssa#S30286041 7-dehydrocholesterol reductase (7dchr) - 1.48 - 1.42 0.0120 
Omy#CF752841 
Sterol regulatory element-binding transcription 
factor 2 (srebp2) - 1.71 - 1.31 0.0170 
Ssa#TC102141 
Cytochrome P450, family 27, subfamily A, 
polypeptide 1 - 3.97 - 1.04 0.0192 
Ssa#STIR16974 7-dehydrocholesterol reductase (7dchr) - 1.46 - 1.31 0.0195 
Ssa#AM402497 Hydroxymethylglutaryl-CoA synthase 1 - 2.39 1.21 0.0199 
Ssa#STIR00031_4 7-dehydrocholesterol reductase (7dchr) - 1.41 - 1.46 0.0212 
Ssa#STIR00098_4 Isopentenyl-diphosphate delta isomerise (ipi) - 2.12 - 1.15 0.0228 
Ssa#S18867829 7-dehydrocholesterol reductase (7dchr) - 1.33 - 1.25 0.0228 
Ssa#DY741343 Lanosterol 14-alpha demethylase - 1.42 - 1.28 0.0346 
Omy#S22913656 Acetoacetyl-CoA synthetase - 1.77 - 2.52 0.0358 
Ssa#STIR00033_3 Mevalonate kinase (mev) - 1.54 - 1.08 0.0393 
Ssa#CA064135 Vigilin 2.80 - 1.22 0.0423 
Ssa#DW582478 
Cytochrome P450, family 8, subfamily B, 
polypeptide 1 - 1.26 - 1.50 0.0449 
Ssa#STIR00102_3 Squalene epoxidase - 2.11 - 1.36 0.0468 
      
Glycerophospholipid synthesis 
Ssa#STIR39152_S Lipid phosphate phosphohydrolase 2 (lpp2) 1.20 1.19 0.0177 
Ssa#KSS4003 Chka protein 1.18 1.53 0.0264 
Ssa#S35538062_S Monoacylglycerol O-acyltransferase 1 (mgat) 1.20 1.51 0.0303 
Ssa#S31963704 Diacylglycerol O-acyltransferase homolog 2 1.41 1.02 0.0358 
Ssa#S48418830 Phosphatidylglycerophosphate synthase 1 - 1.52 - 1.72 0.0369 
     
Fatty acid synthesis 
Ssa#KSS4155 Trans-2-enoyl-CoA reductase, mitochondrial precursor 
- 1.26 - 1.25 0.044 
     
Intracellular fatty acid transport 
Ssa#S35585414 Acyl-CoA-binding protein 10.47 1.65 0.0081 
Ssa#DY703528 Fatty acid-binding protein, intestinal - 1.25 - 1.46 0.0331 
Ssa#CB509140 Fatty acid-binding protein, intestinal - 1.20 - 1.35 0.0375 
Ssa#STIR04578 Fatty acid-binding protein, heart 1.22 1.47 0.0401 
      
Lipid transport 
Ssa#CK898816 
Low density lipoprotein receptor-related protein 1 
(lrp1) - 1.14 - 1.39 0.0341 
Ssa#S32008850 Apolipoprotein A-IV precursor (apoa4a) - 1.43 - 1.01 0.0377 
Omy#BX318293 
Low density lipoprotein receptor-related protein 1 
(lrp1) - 3.61 - 1.67 0.0404 
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Ssa#S18866963 Apolipoprotein A-IV precursor (apoa4b) - 1.39 - 1.43 0.0428 
     
Lipid hydrolysis 
Ssa#S18887340 Acyl-coenzyme A thioesterase 5 1.64 1.18 0.0007 
Ssa#STIR02708 Isoamyl acetate-hydrolyzing esterase 1 homolog  1.54 1.12 0.0013 
Ssa#DW007099 
Similar to patatin-like phospholipase domain 
containing 7 - 3.75 - 2.37 0.0070 
Ssa#S31963297 Acyl-CoA thioesterase 11 1.35 1.38 0.0097 
Ssa#STIR07750 N-acylsphingosine amidohydrolase 1 - 1.14 - 1.34 0.0122 
Ssa#STIR05034 Isoamyl acetate-hydrolyzing esterase 1 homolog 1.74 1.01 0.0208 
Omy#CA366823 Acyl-coenzyme A thioesterase 3 1.33 2.17 0.0248 
Ssa#STIR22551 Lipoprotein lipase (lpl) 1.31 1.31 0.0346 
      
Eicosanoid synthesis and metabolism 
Ssa#TC68569 Thromboxane-A synthase (thas) - 1.33 - 1.67 0.0269 
Ssa#TC110080 Phospholipase A2 (pla2g4) 1.26 1.08 0.0296 
Omy#TC147730 Prostaglandin I2 (prostacyclin) synthase (ptgis) - 2.53 - 4.25 0.0349 
Ssa#S35581706 15-hydroxyprostaglandin dehydrogenase - 1.51 - 1.09 0.0400 
Ssa#EG930234 Arachidonate 5-lipoxygenase (alox5) 1.91 1.55 0.0449 
     
Regulation of lipid metabolism 
Ssa#TC112002 Retinoid X receptor beta 1.00 - 19.09 0.0000 
Ssa#KSS2129 Adiponectin receptor protein 1 - 1.30 - 1.31 0.0098 
Ssa#CA056493 Angiopoietin-like 6 - 1.63 - 1.07 0.0290 
Ssa#S35490606 
Adiponectin, C1Q and collagen domain containing, 
like 1.34 1.66 0.0441 
Ssa#S18888608 Adiponectin receptor protein 1 - 1.38 - 1.40 0.0451 
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Table 5 Validation of microarray results and expression of genes of interest in relation 
to the factor 'n-3 LC-PUFA level'. Values represent the expression ratios between high 
PUFA / low PUFA, for fish containing either low or high total lipid levels in their flesh, 
obtained by microarray analysis or RT-qPCR. Expression ratios in bold were significant by 
REST2008 analysis of RT-qPCR results. 
 Low Lipid 
LH/LL 
 High Lipid 
HH/HL 
Gene Microarray RT-qPCR  Microarray RT-qPCR 
LC-PUFA biosynthesis 
Δ5fad  -1.19   1.17 
Δ6fad  1.13   -1.21 
elovl2  1.14   1.06 
Cholesterol biosynthesis 
ipi -2.13 -3.92  -1.15 1.32 
mev -1.54 -1.51  -1.08 1.06 
7dchr -1.33 to -1.54 -1.47  -1.25 to -1.47 -1.34 
srebp2 -1.72 -1.68  -1.30 1.60 
Lipid transport and lipoprotein metabolism    
lrp1 -1.14 to -3.57 -1.36  -1.39 to -1.67 1.24 
apoA4a -1.43 -1.09  1.00 1.32 
apoA4b -1.39 -1.48  -1.43 -1.10 
lpl 1.31 1.23  1.31 1.38 
Glycerophospholipid synthesis 
lpp2 1.20 -1.19  1.19 1.30 
mgat 1.20 1.04  1.51 1.78 
Eicosanoid biosynthesis 
alox5 1.91 1.48  1.55 1.62 
pla2g4 1.26 -1.08  1.08 1.06 
thas -1.33 -1.08  -1.67 1.34 
ptgis -2.53 -1.25  -4.25 1.27 
Immune response 
mal -22.20 -3.70  -25.00 -5.00 
ccl13 4.40 5.98  3.00 2.14 
trim25 5.20 2.80  6.70 2.51 
lect2 4.60 1.92  7.10 7.57 
Delta5 and 6 fatty acyl desaturases (Δ5fad and Δ6fad); fatty acyl elongase (elovl2); isopentenyl-diphosphate 
isomerase (ipi); mevalonate kinase (mev); 7-dehydrocholesterol reductase (7dchr); sterol regulatory element-
binding protein 2 (srebp2); low density lipoprotein receptor-related protein 1 (lrp1); apolipoprotein A-IV 
(apoa4a and apoa4b); lipoprotein lipase (lpl); lipid phosphate phosphohydrolase 2 (lpp2); monoacylglycerol O-
acyltransferase 1 (mgat); arachidonate 5-lipoxygenase (alox5); phospholipase A2 (pla2g4); thromboxane-A 
synthase (thas); prostaglandin I2 (prostacyclin) synthase (ptgis); myelin and lymphocyte protein (mal); c-c motif 
chemokine 13 precursor (ccl13); tripartite motif-containing protein 25 (trim25); leukocyte cell-derived 
chemotaxin 2 precursor (lect2). 
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Table 6 Validation of microarray results and expression of genes of interest in relation 
to the factor 'Lipid level'. Values represent the expression ratios between high lipid / low 
lipid, for fish containing either low or high n-3 LC-PUFA levels in their flesh, obtained by 
microarray analysis or RT-qPCR. Expression ratios in bold were significant by REST2008 
analysis of RT-qPCR results.  
 Low n-3 LC-PUFA 
HL/LL 
 High n-3 LC-PUFA 
HH/LH 
Gene Microarray RT-qPCR  Microarray RT-qPCR 
LC-PUFA biosynthesis 
Δ5fad  -1.03   1.35 
Δ6fad  1.04   -1.32 
elovl2 -1.28 to -1.41 -1.51  -1.82 to -1.97 -1.62 
Cholesterol biosynthesis    
ipi  -3.95   1.31 
mev  -1.40   1.14 
7dchr  -1.01   1.09 
srebp2  -2.09   1.29 
Lipid transport and lipoprotein metabolism  
lrp1  -1.82   -1.08 
apoA4a  -1.37   -0.95 
apoA4b  -2.43   -1.80 
lpl  -1.18   -1.05 
Immune response 
cfh -1.33 to -1.56 -1.24  -1.56 to -1.69 -1.31 
trim25 -5.64 -2.09  -4.34 -2.33 
lect2 3.16 1.23  4.86 4.84 
Delta5 and 6 fatty acyl desaturases (Δ5fad and Δ6fad); fatty acyl elongase (elovl2); isopentenyl-diphosphate 
isomerase (ipi); mevalonate kinase (mev); 7-dehydrocholesterol reductase (7dchr); sterol regulatory element-
binding protein 2 (srebp2); low density lipoprotein receptor-related protein 1 (lrp1); apolipoprotein A-IV 
(apoa4a and apoa4b); lipoprotein lipase (lpl); complement factor H precursor (cfh); tripartite motif-containing 
protein 25 (trim25); leukocyte cell-derived chemotaxin 2 precursor (lect2). 
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Table 7 Primers used for RT-qPCR analyses  
Transcript Primer sequence (5’-3’) Fragment  Ta Efficiency Accession No. Source 
Δ5fad GTGAATGGGGATCCATAGCA 192 bp 56ºC 0,945 AF478472 1 [9] 
 AAACGAACGGACAACCAGA      
Δ6fad_a CCCCAGACGTTTGTGTCAG 181 bp 56ºC 0,928 AY458652 1 [9] 
 CCTGGATTGTTGCTTTGGAT      
elovl2 CGGGTACAAAATGTGCTGGT 145 bp 60ºC 0,926 TC91192 2  [24] 
 TCTGTTTGCCGATAGCCATT      
ipi ACAGCCCTATGGTTATGTGTCATCTC 230 bp 60ºC 0,985 CK875291 1 [11] 
 CAAGGTGAGGCGAATGTTTGAAC      
mev CCCTTAATCAGGGTCCCAAT 247 bp 60ºC 0,910 DW005667 1 [11] 
 GGTGCTGGTTGATGTCAATG      
7dchr CTTCTGGAATGAGGCATGGT 230 bp 60ºC 0,977 TC99602 2 [11] 
 ACAGGTCCTTCTGGTGGTTG      
srebp2 GACAGGCACAACACAAGGTG 215 bp 60ºC 0,887 DY733476 1 [11] 
 CAGCAGGGGTAAGGGTAGGT      
lrp1 ACCAACCGCATCTACTGGAC 204 bp 60ºC 0,996 CK898816 1 New design 
 CAGATTACCAGCCACCCAGT      
apoA4a CCCAAACCAACACCACTCCT 150 bp 60ºC 0,997 BT047465 1 New design 
 GGTTTATATTTCTCACCCTGCAC      
apoA4b CTCTTGCCCTCTTGATGACTG 154 bp 60ºC 0,918 BT047267 1 New design 
 TGACTCATCAGAGCCAATTCA      
lpl AGGGCGTTAATCCATGTCAG 223 bp 60ºC 0,917 TC84899 2 [8] 
 GACCTTTCAAAAGGGCATGA      
lpp2 TCCGGAAGAACTCGCAATAC 174 bp 60ºC 0,926 NM_001140716 1 [9] 
 ACATCACGTCCACCAAGACA      
mgat TTAACCCAAAGATGCTGCAA 157 bp 60ºC 0,977 EG824440 1 New design 
 CACGCAGTTGTCAGTGGTTT      
alox5 TATCTCCCTCTCCCTCAGTCC 155 bp 56 ºC 0,987 CX727592 1 [57]  
 GGTCAGCAGTGCCATCA      
pla2g4 GTCGCTGGCTGGAGCTGTGG 138 bp 60ºC 0,998 NM_001141333 1 New design 
 AGCCCTATGGGCCCTGGTCA      
thas TGTTCACACGGACCTGATTC 150 bp 60ºC 0,986 NM_001165312 1 New design 
 GACCGGATCGTCATTCTGTT      
ptgis GCGTGTTTGTGGTCATTACG 247 bp 60ºC 0,836 GE778709 1 New design 
 TTCCCTTAGCAAGGTCTGGA      
mal GGCCTCAGTCAAAGAGGAGA 156 bp 60ºC 0,946 NM_001141320 1 New design 
43 
 
 GGGGAGTGCACACTTTAGGA      
ccl13 CGAGGATCCCTCTTCAACAA 178 bp 60ºC 0,996 EG831431 1 New design 
 ATCGTCGACTAGGCAGCAGT      
trim25 GCAGGGTCCTATCTCATCCA 215 bp 60ºC 0,951 BT048046 1 New design 
 GGACTGGACCTTTTTATTCTCTCA      
lect2 CTGTGTTGTCAGAGTGCGAGATGGT 150 bp 60ºC 0,996 BT050009 1 [58]  
 TACACACAATGTCCAGGCCCTGA      
cfh TGTGATGATGGAGAGATGCAG 193 bp 60ºC 0,966 TC141997 2 New design 
 CAAGCGACAAAGAAACCACA      
      
Reference genes*      
elf-1α CTGCCCCTCCAGGACGTTTACAA 175 bp 60ºC 1.000 AF321836 1 [11] 
 CACCGGGCATAGCCGATTCC      
β-actin ACATCAAGGAGAAGCTGTGC 141 bp 56ºC 0.939 AF012125 1 [11] 
 GACAACGGAACCTCTCGTTA      
1 GenBank (http://www.ncbi.nlm.nih.gov/) 
2 Atlantic salmon Gene Index (http://compbio.dfci.harvard.edu/tgi/) 
* geNorm average stability (M value) of reference genes = 0.514 [59] 
Additional file 1: Relationship between total lipid level and n-3 LC-PUFA content. 
The graphs show the relationship between total lipid level (g/100g flesh) and n-3 LC-
PUFA content as either a relative value (µg/mg lipid) – top graph – or an absolute 
amount (mg/100g flesh) – bottom graph. Indicated are the correlation coefficients (r) 
and associated p-values between both lipid composition parameters. Squares around the 
data points indicate the four families which were used for molecular analysis.   
	  
Additional file 2: Gene Ontology terms showing significant enrichment in the list of features affected by the 'total lipid' factor. 
GO analysis was conducted at p<0.05 after two-way ANOVA analysis of the microarray results (p<0.05; fold change cut-off of 1.2; 
with Benjamini-Hochberg multiple testing correction).  
GO ACCESSION GO Term Corrected 
p-value 
% Count in 
Selection 
% Count 
in Total 
GO:0050778 positive regulation of immune response 2,9E-07 20 0,25 
GO:0050776 regulation of immune response 2,9E-07 20 0,28 
GO:0002684 positive regulation of immune system process 6,2E-07 20 0,32 
GO:0048584 positive regulation of response to stimulus 8,7E-07 20 0,28 
GO:0002682 regulation of immune system process 2,6E-06 20 0,38 
GO:0048583 regulation of response to stimulus 4,9E-05 20 0,37 
GO:0002699 positive regulation of immune effector process 1,9E-04 16 0,08 
GO:0002697 regulation of immune effector process 4,9E-04 16 0,10 
GO:0006954 inflammatory response 9,7E-04 24 0,40 
GO:0001819 positive regulation of cytokine production 1,1E-02 16 0,07 
GO:0016614 oxidoreductase activity, acting on CH-OH group of donors 1,4E-02 30 0,63 
GO:0006952|GO:0002217|GO:0042829 defense response 1,4E-02 28 0,76 
GO:0004616 phosphogluconate dehydrogenase (decarboxylating) activity 1,9E-02 16 0,07 
GO:0006739 NADP metabolic process 2,0E-02 16 0,20 
GO:0002708 positive regulation of lymphocyte mediated immunity 2,6E-02 12 0,06 
GO:0002706 regulation of lymphocyte mediated immunity 2,6E-02 12 0,06 
GO:0002705 positive regulation of leukocyte mediated immunity 2,6E-02 12 0,06 
GO:0002703 regulation of leukocyte mediated immunity 2,6E-02 12 0,06 
GO:0001817 regulation of cytokine production 2,7E-02 16 0,08 
GO:0019863 IgE binding 3,3E-02 12 0,04 
GO:0006766 vitamin metabolic process 3,6E-02 18 0,48 
GO:0002673 regulation of acute inflammatory response 4,4E-02 12 0,05 
GO:0002675 positive regulation of acute inflammatory response 4,4E-02 12 0,05 
GO:0002712 regulation of B cell mediated immunity 4,4E-02 12 0,05 
GO:0002714 positive regulation of B cell mediated immunity 4,4E-02 12 0,05 
GO:0002819 regulation of adaptive immune response 4,4E-02 12 0,05 
GO:0002821 positive regulation of adaptive immune response 4,4E-02 12 0,05 
GO:0002822 
regulation of adaptive immune response based on somatic recombination of 
immune receptors built from immunoglobulin superfamily domains 4,4E-02 12 0,05 
GO:0002824 
positive regulation of adaptive immune response based on somatic 
recombination of immune receptors built from immunoglobulin 
superfamily domains 4,4E-02 12 0,05 
GO:0002861 regulation of inflammatory response to antigenic stimulus 4,4E-02 12 0,05 
GO:0002863 positive regulation of inflammatory response to antigenic stimulus 4,4E-02 12 0,05 
GO:0002864 regulation of acute inflammatory response to antigenic stimulus 4,4E-02 12 0,05 
GO:0002866 positive regulation of acute inflammatory response to antigenic stimulus 4,4E-02 12 0,05 
GO:0002883 regulation of hypersensitivity 4,4E-02 12 0,05 
GO:0002885 positive regulation of hypersensitivity 4,4E-02 12 0,05 
GO:0002889 regulation of immunoglobulin mediated immune response 4,4E-02 12 0,05 
GO:0002891 positive regulation of immunoglobulin mediated immune response 4,4E-02 12 0,05 
GO:0006098 pentose-phosphate shunt 4,4E-02 16 0,20 
GO:0006740 NADPH regeneration 4,4E-02 16 0,20 
GO:0006769 nicotinamide metabolic process 4,4E-02 16 0,23 
GO:0016616 
oxidoreductase activity, acting on the CH-OH group of donors, NAD or 
NADP as acceptor 4,4E-02 30 0,61 
GO:0019814 immunoglobulin complex 4,4E-02 14 0,08 
GO:0019882|GO:0030333 antigen processing and presentation 4,4E-02 14 0,24 
	  
Additional file 3: Distribution of IPN resistance scores in relation to flesh lipid 
phenotypes. The plots show estimated breeding values (EBV) for IPN survival (logit 
transformation of data where 0-dead and 1-alive), assessed by a freshwater experimental 
challenge, in relation to either total lipid level (g/100g flesh) (upper panel) or absolute n-3 
LC-PUFA content (mg/100g flesh) (lower panel) of all families in the selection program. 
Indicated (squares around the data points) are the four families used for molecular analysis.   
	  
Additional file 4: Genes similarly regulated in pair-wise comparisons of families 
containing H and L n-3 LC-PUFA flesh contents, at each one of the total lipid 
levels. Two t-tests (unpaired unequal variance, Welch, asymptotic) with no multiple 
testing correction, at p < 0.05 and fold change >1.2, were performed, each comparing 
the two families presenting higher and lower n-3 LC-PUFA contents at either one of the 
total lipid levels: HH/HL and LH/LL. This returned a list of 1604 or 1305 entities for 
the comparison in the low or high total lipid grouping, respectively. A Venn diagram 
was subsequently performed with these two lists and a Venn list containing only the 
genes that were present in both t-test lists was retrieved. The Venn list contained 149 
entities but, of these, only 64 entities presented a similar regulation (up- or down-
regulated in both lists). These were then categorized according to their biological 
function (9% unknowns) and are presented in the table. Indicated are also the probe 
names, the expression ratio for HH/HL and LH/LL comparisons, and their respective p-
values. Percent representation of genes by category of biological function (after 
removing unknown and genes with miscellaneous function, as well as repeated probes 
for the same gene) is also shown. 
Probe name Gene Hi/Lo LC-PUFA p- value 
  H Lipid 
HH/HL 
L Lipid 
LH/LL 
H Lipid 
HH/HL 
L Lipid 
LH/LL 
      
Metabolism (9%)  
  
Energy metabolism (3%)  
Ssa#S31991256 Isocitrate dehydrogenase 3 (nad+) - 1.7 - 1.9 0.0233 0.0046 
      
Xenobiotic and oxidant metabolism (6%)  
Ssa#STIR00161_3 Cytochrome P450 1A 1.8 2.5 0.0045 0.0047 
Con_CANDS_13 Cytochrome P450 1A 1.4 2.0 0.0071 0.0101 
Ssa#S18892279 Cytochrome P450 1A 1.4 1.8 0.0112 0.0041 
Ssa#STIR05682 Peroxiredoxin 5 1.3 1.4 0.0122 0.0207 
Ssa#STIR00161_4 Cytochrome P450 1A 1.5 2.1 0.0210 0.0145 
Ssa#STIR00161_2 Cytochrome P450 1A 1.4 1.9 0.0286 0.0019 
      
Translation (6%)  
Ssa#KSS2048 Mitochondrial ribosomal protein S33 - 1.8 - 1.9 0.0028 0.0171 
Ssa#S30281303 Mitochondrial 28S ribosomal protein S33 - 1.7 - 1.7 0.0105 0.0395 
Ssa#S18867312 Ribonuclease UK114 1.4 1.4 0.0132 0.0030 
      
Regulation of transcription (28%)  
Ssa#S35481301 TIP120 protein 3.4 3.1 0.0019 0.0471 
Ssa#S35664778 Zinc finger protein 41 1.5 1.5 0.0037 0.0245 
Omy#S18104058 Zinc finger protein 235 2.3 4.1 0.0208 0.0006 
Ssa#S31964227 Similar to GTF2I repeat domain containing 2 2.5 3.3 0.0224 0.0161 
Ssa#CN181117 U2-associated protein SR140 (140 kDa Ser/Arg-rich domain protein) 3.1 4.4 0.0242 0.0068 
Ssa#S18880068 SET and MYND domain-containing protein 3 1.8 2.1 0.0244 0.0313 
Ssa#S35500885 Transcription factor 15 3.7 3.5 0.0262 0.0355 
Omy#TC171818 Zinc finger CCCH domain-containing protein 14 1.3 1.5 0.0279 0.0287 
Ssa#S31985656 Prolactin regulatory element-binding protein 2.4 4.4 0.0329 0.0116 
Ssa#TC97482 CREB binding protein transcript variant 2.9 3.6 0.0355 0.0342 
  
Signalling and protein modification (22%)  
Ssa#S35552908 Tyrosine 3-monooxygenase/tryptophan 5-monooxygenase activation 
protein, epsilon polypeptide 
- 2.1 - 1.6 0.0037 0.0395 
Ssa#CA055651 Serine/threonine-protein phosphatase 6 13.0 - 6.5 0.0091 0.0193 
Ssa#STIR07369 Serine threonine protein kinase raf1 1.3 1.8 0.0118 0.0033 
Omy#TC167859 Regulator of calcineurin family member - 1.4 - 1.4 0.0139 0.0418 
Ssa#S30241573 Tyrosine 3-monooxygenase/tryptophan 5-monooxygenase activation 
protein, epsilon polypeptide 
- 1.5 1.3 0.0187 0.0499 
Ssa#STIR31840 Sphingomyelin phosphodiesterase acid transcript variant 1 2.3 2.1 0.0238 0.0003 
Ssa#S23659857 Sphingomyelin phosphodiesterase acid transcript variant 1 2.0 1.6 0.0278 0.0100 
Ssa#STIR23254 Serine/threonine-protein phosphatase 2A regulatory subunit B 
subunit gamma 
1.2 1.7 0.0286 0.0053 
Ssa#S35559485 P2Y purinoceptor 1 1.4 1.4 0.0414 0.0046 
Ssa#STIR11129 Ras-related protein Rap-2b precursor putative - 4.5 - 5.8 0.0460 0.0071 
      
Immune response (36%)  
Ssa#S35581943 Myelin and lymphocyte protein - 25.0 - 22.2 0.0004 0.0059 
Ssa#S35558945 Tripartite motif-containing protein 25 6.5 4.8 0.0011 0.0240 
Ssa#S35536179 novel NACHT domain containing protein 1.8 2.4 0.0016 0.0018 
Ssa#S35516341 Tripartite motif-containing protein 25 6.7 5.2 0.0023 0.0044 
Ssa#STIR02298 C-C motif chemokine 13 precursor putative 3.0 4.4 0.0029 0.0015 
Ssa#TC70262 Cathepsin K 2.3 1.4 0.0050 0.0153 
Ssa#KSS3969 Leukocyte cell-derived chemotaxin 2 precursor 7.1 4.6 0.0071 0.0008 
Ssa#S30265745 Bleomycin hydrolase - 1.6 - 1.6 0.0127 0.0056 
Ssa#TC93758 BOLA class I histocompatibility antigen, alpha chain BL3-7 
precursor 
- 9.0 - 18.6 0.0133 0.0473 
Ssa#STIR21287 Solute carrier family 30 (zinc transporter)member 7 1.5 2.1 0.0134 0.0006 
Ssa#STIR29382 Rhamnose-binding lectin WCL1 1.4 1.5 0.0165 0.0375 
Ssa#S29966058 MHC class I antigen 8.4 1.9 0.0171 0.0457 
Ssa#S35566535 CD4 1.6 1.6 0.0266 0.0040 
Ssa#S19108411 Rhamnose-binding lectin WCL1 1.3 1.5 0.0343 0.0111 
Ssa#S35509469 GTPase IMAP family member 7 1.7 4.0 0.0417 0.0043 
  
Miscellaneous/unknown function  
Ssa#STIR09736 Transmembrane protein 42 1.9 2.3 0.0004 0.0005 
Ssa#STIR02934 Ripply2 protein - 2.0 - 2.0 0.0009 0.0242 
Ssa#DW552272 Usher syndrome 1C (autosomal recessive, severe) - 16.2 - 8.1 0.0037 0.0308 
Ssa#S18842295 Alveolin 4.6 1.7 0.0081 0.0001 
Ssa#TC110572 Usher syndrome 1C (autosomal recessive, severe) - 9.1 - 3.6 0.0093 0.0415 
Omy#CX031967 X-ray repair complementing defective repair in Chinese hamster cells 
3 
- 2.1 - 3.1 0.0174 0.0280 
Ssa#S30242447 Serine protease HTRA1 - 2.3 - 3.8 0.0281 0.0361 
Omy#S15322430 Oxidative stress induced growth inhibitor 1 - 1.4 - 1.3 0.0312 0.0489 
Ssa#CB517995 Neuroligin 3 3.8 4.3 0.0341 0.0344 
Ssa#DY726487 WD repeat domain 44 - 3.8 - 3.5 0.0428 0.0098 
Ssa#S35564744 Claudin 10 2.1 4.6 0.0473 0.0191 
Omy#S19712209 N-acylglucosamine 2-epimerase - 2.7 - 6.0 0.0482 0.0382 
Ssa#STIR11043 Golgi autoantigen, golgin subfamily b, macrogolgin (with 
transmembrane signal), 1 (GOLGB1) 
- 1.4 - 1.8 0.0500 0.0118 
	  
	  
